168 related articles for article (PubMed ID: 36931346)
1. From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer.
Gonzales-Aloy E; Ahmed-Cox A; Tsoli M; Ziegler DS; Kavallaris M
Adv Drug Deliv Rev; 2023 May; 196():114777. PubMed ID: 36931346
[TBL] [Abstract][Full Text] [Related]
2. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
Wang D; Wang C; Wang L; Chen Y
Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
[TBL] [Abstract][Full Text] [Related]
4. The influence of the blood-brain barrier in the treatment of brain tumours.
Rathi S; Griffith JI; Zhang W; Zhang W; Oh JH; Talele S; Sarkaria JN; Elmquist WF
J Intern Med; 2022 Jul; 292(1):3-30. PubMed ID: 35040235
[TBL] [Abstract][Full Text] [Related]
5. Blood-brain-barrier organoids for investigating the permeability of CNS therapeutics.
Bergmann S; Lawler SE; Qu Y; Fadzen CM; Wolfe JM; Regan MS; Pentelute BL; Agar NYR; Cho CF
Nat Protoc; 2018 Dec; 13(12):2827-2843. PubMed ID: 30382243
[TBL] [Abstract][Full Text] [Related]
6. Investigating receptor-mediated antibody transcytosis using blood-brain barrier organoid arrays.
Simonneau C; Duschmalé M; Gavrilov A; Brandenberg N; Hoehnel S; Ceroni C; Lassalle E; Kassianidou E; Knoetgen H; Niewoehner J; Villaseñor R
Fluids Barriers CNS; 2021 Sep; 18(1):43. PubMed ID: 34544422
[TBL] [Abstract][Full Text] [Related]
7. Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish.
Le Joncour V; Karaman S; Laakkonen PM
J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058900
[TBL] [Abstract][Full Text] [Related]
8. Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers.
Farshbaf M; Mojarad-Jabali S; Hemmati S; Khosroushahi AY; Motasadizadeh H; Zarebkohan A; Valizadeh H
J Control Release; 2022 May; 345():371-384. PubMed ID: 35301054
[TBL] [Abstract][Full Text] [Related]
9. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
Deligne C; Hachani J; Duban-Deweer S; Meignan S; Leblond P; Carcaboso AM; Sano Y; Shimizu F; Kanda T; Gosselet F; Dehouck MP; Mysiorek C
Fluids Barriers CNS; 2020 Jun; 17(1):37. PubMed ID: 32487241
[TBL] [Abstract][Full Text] [Related]
10. Initial contact of glioblastoma cells with existing normal brain endothelial cells strengthen the barrier function via fibroblast growth factor 2 secretion: a new in vitro blood-brain barrier model.
Toyoda K; Tanaka K; Nakagawa S; Thuy DH; Ujifuku K; Kamada K; Hayashi K; Matsuo T; Nagata I; Niwa M
Cell Mol Neurobiol; 2013 May; 33(4):489-501. PubMed ID: 23385422
[TBL] [Abstract][Full Text] [Related]
11. Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases.
Chen L; Zeng D; Xu N; Li C; Zhang W; Zhu X; Gao Y; Chen PR; Lin J
ACS Appl Mater Interfaces; 2019 Nov; 11(45):41889-41897. PubMed ID: 31615203
[TBL] [Abstract][Full Text] [Related]
12. An overview of in vitro 3D models of the blood-brain barrier as a tool to predict the in vivo permeability of nanomedicines.
Pérez-López A; Torres-Suárez AI; Martín-Sabroso C; Aparicio-Blanco J
Adv Drug Deliv Rev; 2023 May; 196():114816. PubMed ID: 37003488
[TBL] [Abstract][Full Text] [Related]
13. Novel Treatment Approaches for Brain Tumour from a Blood-Brain Barrier Perspective.
Wu SK; Tsai CL; Hynynen K
Handb Exp Pharmacol; 2022; 273():351-364. PubMed ID: 33454856
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicine for brain cancer.
Quader S; Kataoka K; Cabral H
Adv Drug Deliv Rev; 2022 Mar; 182():114115. PubMed ID: 35077821
[TBL] [Abstract][Full Text] [Related]
15. Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents.
Cho CF; Wolfe JM; Fadzen CM; Calligaris D; Hornburg K; Chiocca EA; Agar NYR; Pentelute BL; Lawler SE
Nat Commun; 2017 Jun; 8():15623. PubMed ID: 28585535
[TBL] [Abstract][Full Text] [Related]
16. Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies.
Huang J; Li YB; Charlebois C; Nguyen T; Liu Z; Bloemberg D; Zafer A; Baumann E; Sodja C; Leclerc S; Fewell G; Liu Q; Prabhakarpandian B; McComb S; Stanimirovic DB; Jezierski A
Fluids Barriers CNS; 2022 Jun; 19(1):38. PubMed ID: 35650594
[TBL] [Abstract][Full Text] [Related]
17. A pump-free tricellular blood-brain barrier on-a-chip model to understand barrier property and evaluate drug response.
Yu F; Kumar NDS; Foo LC; Ng SH; Hunziker W; Choudhury D
Biotechnol Bioeng; 2020 Apr; 117(4):1127-1136. PubMed ID: 31885078
[TBL] [Abstract][Full Text] [Related]
18. Organization of Endothelial Cells, Pericytes, and Astrocytes into a 3D Microfluidic in Vitro Model of the Blood-Brain Barrier.
Wang JD; Khafagy el-S; Khanafer K; Takayama S; ElSayed ME
Mol Pharm; 2016 Mar; 13(3):895-906. PubMed ID: 26751280
[TBL] [Abstract][Full Text] [Related]
19. Applications and Considerations for Microfluidic Systems To Model the Blood-Brain Barrier.
Floryanzia SD; Nance E
ACS Appl Bio Mater; 2023 Sep; 6(9):3617-3632. PubMed ID: 37582179
[TBL] [Abstract][Full Text] [Related]
20. Tailoring functional nanostructured lipid carriers for glioblastoma treatment with enhanced permeability through in-vitro 3D BBB/BBTB models.
Zwain T; Alder JE; Sabagh B; Shaw A; Burrow AJ; Singh KK
Mater Sci Eng C Mater Biol Appl; 2021 Feb; 121():111774. PubMed ID: 33579439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
